Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
India in the Changing Landscape of Life-Sciences Research & Development
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Subscribe To Our Newsletter & Stay Updated
